Apimeds Pharmaceuticals US (APUS) Cash & Equivalents (2023 - 2025)

Apimeds Pharmaceuticals US's Cash & Equivalents history runs 3 years deep, the most recent figure standing at $1.6 million for Q4 2025.

• Quarterly Cash & Equivalents rose 47270.62% year-over-year to $1.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.6 million (up 47270.62% YoY) and the FY2025 annual result came in at $1.6 million, up 47270.62% from the prior year.
• Cash & Equivalents was $1.6 million for Q4 2025 at Apimeds Pharmaceuticals US, down from $7.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $8.7 million in Q2 2025 and bottomed at $3455.0 in Q4 2024.
• A 3-year average of $3.0 million and a median of $1.0 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents slumped 99.16% — and 2025, when it surged 47270.62%.
• Apimeds Pharmaceuticals US's Cash & Equivalents stood at $410481.0 in 2023, then slumped by 99.16% to $3455.0 in 2024, then jumped by 47270.62% to $1.6 million in 2025.
• Business Quant data shows APUS's Cash & Equivalents at $1.6 million in Q4 2025, $7.0 million in Q3 2025, and $8.7 million in Q2 2025.